Lung Cancer
Consistent efficacy of osimertinib in Chinese and global population
Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC
Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy
Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy
Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC
Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC
Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC
ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy
Savolitinib is effective in patients with MET-mutated NSCLC
Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC
Updated results of CameL-sq trial confirm benefit of camrelizumab
No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC
In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC
Durvalumab after sequential CRT safe in stage III, unresectable NSCLC
No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC
Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
Total metabolic tumour volume: a new potential prognostic factor in SCLC
Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy
Characteristics of long-term survivors in the CASPIAN trial
Outcomes of real-world CANTABRICO trial match results from CASPIAN
Lung cancer diagnosis with liquid biopsy of peripheral blood cells
Rare EGFR mutations as oncogenic drivers
Decline in lung cancer mortality is almost exclusive to men
No benefit to adding radiation to PD-L1/CTLA-4 therapy in resistant metastatic NSCLC
Lung-cancer screening leads to overdiagnosis among nonsmoking Asian women
It’s never too late to quit smoking, even after lung-cancer diagnosis
No support for adjuvant radiation in resected N2 non-small-cell lung cancer
Atezolizumab, nivolumab tied to longer survival than docetaxel in advanced lung cancer
Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC
Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM
Adjuvant atezolizumab lowers relapse rate in resected NSCLC
Three-year OS follow-up from CASPIAN trial
TCR clonality predicts pembrolizumab response in NSCLC
Lung cancer screening with CT urged for head/neck cancer survivors
Long-term survival in NSCLC similar with stereotactic ablative radiotherapy or surgery
ESMO 2021 Highlights Podcast
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
Genomic profiling of NSCLC may be predictive of immunotherapy response
New preoperative classification scheme proposed for oligometastatic NSCLC
Prognostic factors in immunotherapy for advanced lung cancer
GLCC survey: Increased demand for patient-support services during COVID-19 pandemic
Lung Cancer Europe patient survey identifies gaps in lung cancer care
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
COVID-19 sees decreased lung cancer diagnoses and use of support services in US
Experiences of lung cancer patients during COVID-19: survey finds room for improvement
Atezolizumab promising for treating NSCLC brain metastases
Interim results of nivolumab + rucaparib in SCLC
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
Real-world data shows inferior survival compared with IMpower150 results
NSCLC metastases also benefit from nivolumab + ipilimumab + chemo
Lung cancer, non-Hodgkin lymphoma biggest contributors to life-years lost to cancer in transplant patients
Antibody-drug combo sparks lung tumor shrinkage in most NSCLC patients with HER2 mutation
Pretreatment levels of ctDNA may predict survival in some lung-cancer patients
Triple therapy boosts survival in metastatic non-small-cell lung cancer
Lung-cancer trial enrollment takes a hit amid COVID-19
Air pollution a global contributor to lung-cancer deaths, with variation among countries
Upfront add-on veliparib may not help smokers with lung cancer live longer
Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC
Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC
Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
Icotinib tops chemo as adjuvant therapy for EGFR-mutant NSCLC
Durvalumab after chemoradiation proven safe in elderly NSCLC patients
Doubling overall survival in US veterans with stage 3 non-small cell lung cancer
5-year PACIFIC data hold strong in NSCLC
Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy
Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab
No benefit of adding metformin to chemoradiotherapy in locally advanced lung cancer
Post-diagnosis smoking cessation tied to improved lung cancer outcomes
Tobacco biomarkers do not improve prediction of lung cancer risk
Pralsetinib promising new agent for RET fusion-protein-positive lung cancer
In early lung cancer, immunotherapy plus targeted radiation may up response rate
Lung-cancer screening can spot people at high risk for aortic stenosis
Immunotherapy offers no real-world survival boost in older people with lung cancer
Adding neoadjuvant nivolumab to chemo shows clear benefit in resectable non-small-cell lung cancer
Phase III ADAURA Trial: CNS Recurrences slashed for NSCLC
Chemoimmunotherapy is effective in a subset of small cell lung cancer patients
Atezolizumab with SABR for high-risk early-stage NSCLC: initial results
4-year PACIFIC data hold strong in NSCLC
ES-SCLC: CASPIAN trial perspectives from Prof. Jonathan Goldman
Amivantamab/lazertinib benefits patients with EGFR-mutated NCSLC
Neoadjuvant atezolizumab may be worthwhile in some patients with resectable lung cancer
Gemcitabine maintenance after first-line chemo prolongs PFS in malignant mesothelioma
Lung-cancer screening in at-risk never-smokers catches early disease
Nivolumab boosts survival in relapsed malignant mesothelioma
COVID has led to a drop in lung cancer diagnosis, more deaths
Proposed revisions to lung-cancer-screening eligibility criteria may not go far enough
Immunotherapy plus chemo bests chemo alone in Asians with advanced NSCLC
Invasive tests prompted by cancer screening show high real-world complication rate
Radiologists seem to agree with guidelines for lung-nodule evaluation
No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC
Best treatment of extensive-stage lung cancer includes PD-L1 inhibitor and etoposide
Lorlatinib surpasses crizotinib as first-line treatment for advanced ALK+ lung cancer
Lung cancer screening: Most patients not eligible 1-2 years prior to diagnosis
Biomarkers: a novel tool to improve lung nodule classification
Distinct changes in lung microbiome precede clinical diagnosis of lung cancer
Social smoking: Do not underestimate the risks
Atezolizumab results show benefit for selected NSCLC patients
Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study
AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain
Higher thrombotic risk in NSCLC patient with ALK rearrangement
ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint
Adjuvant osimertinib in NSCLC: practice changing ADAURA trial
ES-SCLC: pembrolizumab KEYNOTE-604 data
Second-line gemcitabine plus ramucirumab significantly improves overall survival
Tiragolumab and atezolizumab: ORR in NSCLC
MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib
Neural network identifies high-risk smokers for lung-cancer screening
Thoracic cancers versus COVID-19
Mixed data: AMG 510 in tumours with KRASG12C
Ceritinib in ALK+ NSCLC brain metastases
Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma
Frontline ipilimumab/nivolumab improves OS in advanced NCLSC
First-line osimertinib significantly lengthens OS in NSCLC
Liquid biopsy to decide the best treatment for NSCLC
First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression
Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC
Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities
Promising phase 1 results of novel KRAS-inhibitor in NSCLC
Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer
Novel targets in mesothelioma may aid in developing treatment strategies
Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC
Overcoming the challenges of immunotherapy in non–small cell lung cancer
Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC
Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC
Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC
Lurbinectedin shows promise as second-line therapy for SCLC
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Early results from TAK-788 in NSCLC with EGFR exon 20 insertions
Experiences from Germany
Post-discontinuation immunotherapy in PACIFIC
Molecular characteristics of SCLC
I-O monotherapy
Incidence and local treatment
Tumour, node, and metastasis (TNM) staging system
Combo I-O plus chemotherapy
Brain irradiation as treatment option
Other I-O combinations
Experiences from France
Post-study immunotherapy in MYSTIC
Predictive diagnostics for I-O
Electromagnetic navigation bronchoscopy
Genomic and immune profiling
Treatment options in early NSCLC
Immunotherapy in SCLC: trial data
Systemic therapy of brain metastases
How can societies help to implement personalised treatment?
Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer
Unmet needs in surgical management of malignant pleural mesothelioma
PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib
Next generation immunotherapy in non-small-cell lung cancer
Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer
Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer
Combination therapies: Where are we in 2018?
Entrectinib treatment in patients with ROS1+ NSCLC
Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer
Benefits of chest CT screening
Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer
